In a significant development for the treatment of eye infections, the biotechnology company VisiRose has unveiled its innovative Photodynamic Antimicrobial Therapy with Rose Bengal (RB PDAT). This groundbreaking treatment is the result of collaboration between the Bascom Palmer Eye Institute at the Miller School of Medicine at the University of Miami and Provectus Biopharmaceuticals.
RB PDAT represents an innovative and non-invasive solution aimed at treating infectious keratitis and other severe eye infections. It uses a formulation of the bioactive synthetic molecule Rose Bengal Sodium (RBS), along with a medical device that utilizes light to effectively combat bacteria, fungi, and parasites. This new approach could provide a definitive response to the growing problem of antimicrobial resistance (AMR), providing a broad-spectrum therapy that has already shown positive results in clinical trials in countries such as the United States, India, Brazil, and Mexico.
“RB PDAT is a revolutionary and non-invasive treatment that offers new hope to patients by preserving their vision and fighting infections with the help of light,” commented Jean-Marie Parel, director of the Ophthalmic Biophysics Center at BPEI. Meanwhile, Guillermo Amescua, professor of ophthalmology, highlighted the significance of VisiRose in bringing the therapy from the laboratory to a globally accessible clinical practice.
VisiRose aims to bridge the gap between innovation and its tangible impact on patients’ lives, with the goal of addressing gaps in the global ophthalmic market, which is valued at $60 billion. Alongside the University of Miami and Provectus, the company is aiming to commercialize this revolutionary therapy, particularly in regions affected by antimicrobial resistance and limited access to appropriate treatments.
To date, more than 500 patients have received this treatment, showing encouraging results especially in cases where traditional therapies have been ineffective. VisiRose is steadfast in its mission to transform lives and improve the future landscape of ophthalmic care.
via: MiMub in Spanish
